NOVARTIS AG

NOVARTIS AG has an estimated net worth of $1.67 Billion. This is based on reported shares across multiple companies, which include Cellular Biomedicine Group, Inc., Poseida Therapeutics, Inc., Akouos, Inc., Forma Therapeutics Holdings, Inc.,, Galera Therapeutics, Inc., BICYCLE THERAPEUTICS plc, AveXis, Inc., Surface Oncology, Inc., Homology Medicines, Inc., Intellia Therapeutics, Inc., AILERON THERAPEUTICS INC, Altimmune, Inc., Aerpio Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., Aeglea BioTherapeutics, Inc., PROTEOSTASIS THERAPEUTICS, INC., Tokai Pharmaceuticals Inc, Marina Biotech, Inc., , ALNYLAM PHARMACEUTICALS, INC., EON LABS INC, IDENIX PHARMACEUTICALS INC, CHIRON CORP, PRECISION BIOSCIENCES INC, and Tourmaline Bio, Inc..

2012 was NOVARTIS AG's most active year for acquiring shares with 19 total transactions. NOVARTIS AG's most active month to acquire stocks was the month of January. 2011 was NOVARTIS AG's most active year for disposing of shares, totalling 79 transactions. NOVARTIS AG's most active month to dispose stocks was the month of December. 2005 saw NOVARTIS AG paying a total of $405,141,038.65 for 12,022,776 shares, this is the most they've acquired in one year. In 2014 NOVARTIS AG cashed out on 78,558,820 shares for a total of $816,566,346.40, their largest year based on trade value.